Expression of Multidrug Resistance-Associated Protein 2 in Human Gallbladder Carcinoma

Table 1

Relationship between the expression of MRP2 in GBCA and clinicopathological characteristics.

Characteristics	Total	MRP2 expression
		Positive (%)	Negative (%)	𝑃 value
Age (year-old)
≥64	71	42 (59.2)	29 (40.8)	0.153
<64	72	34 (47.2)	38 (52.8)
Sex
Man	70	38 (54.3)	32 (45.7)	0.789
Woman	73	38 (52.1)	35 (47.9)
Histologic grade
1 (well differentiated)	56	29 (51.8)	27 (48.2)
2 (moderately differentiated)	66	38 (57.6)	28 (42.4)	0.736
3 (poorly differentiated)	21	9 (42.9)	12 (57.1)
Tumor size (cm)
≥2.5	72	38 (52.8)	34 (47.2)	0.929
<2.5	71	38 (53.5)	33 (46.5)
Pathological T stage
pT1	23	9 (39.1)	14 (60.9)
pT2	80	47 (58.8)	33 (41.3)	0.743
pT3	28	14 (50.0)	14 (50.0)
pT4	12	6 (50.0)	6 (50.0)
Nodal metastasis
Present	50	26 (52.0)	24 (48.0)
Absent	83	47 (56.6)	36 (43.4)	0.604
Unknown	10
Distant metastasis
Present	25	13 (52.0)	12 (48.0)	0.899
Absent	118	63 (53.4)	55 (46.6)
TNM Stage
I	17	6 (35.3)	11 (64.7)
II	43	29 (52.4)	14 (32.6)
III	63	33 (52.4)	30 (47.6)	0.868
IV	10	5 (50.0)	5 (50.0)
Unknown	10
Local recurrence
Present	25	18 (72.0)	7 (28.0)	0.038*
Absent	118	58 (49.2)	60 (50.8)
Lymphatic invasion
Present	60	38 (63.3)	22 (36.7)	0.038*
Absent	83	38 (45.8)	45 (54.2)
Vascular invasion
Present	36	25 (69.4)	11 (30.6)	0.023*
Absent	107	51 (47.7)	56 (52.3)
Perineural invasion
Present	29	22 (75.9)	7 (24.1)	0.006*
Absent	114	54 (47.4)	60 (52.6)
Resection margin involvement
Present	17	10 (58.8)	7 (41.2)	0.617
Absent	126	66 (52.4)	60 (47.6)

∗Statistically significant.